rna
interfer
mediat
short
interf
rna
sirna
shown
activ
wide
rang
virus
promis
new
antivir
therapi
use
multipl
sirna
target
conserv
area
genom
allow
increas
chanc
antivir
activ
differ
viral
strain
also
help
prevent
emerg
escap
mutant
studi
four
sirna
design
target
area
conserv
sequenc
diverg
strain
venezuelan
equin
enceph
viru
veev
pool
sirna
inhibit
replic
six
strain
veev
test
singl
nucleotid
mismatch
extrem
end
one
sirna
sens
strand
affect
antivir
activ
mutat
toler
two
strain
veev
test
abil
overcom
inhibitori
effect
rna
interfer
follow
consecut
incub
presenc
sirna
one
strain
remain
suscept
throughout
cours
experi
strain
becam
resist
activ
sirna
sequenc
analysi
sirna
target
site
strain
show
mutat
gener
indic
viru
may
becom
resist
manner
absenc
effect
antivir
drug
vaccin
combat
veev
infect
sirna
offer
potenti
new
therapeut
approach
antimicrobi
agent
caution
need
exercis
respect
gener
resist
crown
venezuelan
equin
enceph
viru
veev
small
envelop
rna
viru
belong
alphaviru
genu
genom
positivesens
singlestrand
rna
approxim
kb
cap
end
polyadenyl
end
twothird
genom
encod
four
nonstructur
protein
requir
rna
replic
subgenom
messeng
rna
equival
onethird
genom
encod
three
structur
protein
capsid
two
small
cleavag
product
strauss
strauss
infect
nonstructur
protein
translat
directli
genom
rna
also
act
templat
synthesi
negativesens
strand
negativesens
strand
provid
templat
synthesi
genom
subgenom
rna
strauss
strauss
releas
tel
fax
email
address
lmobrien
dstlgovuk
progeni
viru
occur
approxim
h
entri
host
cell
veev
occur
natur
south
america
southern
unit
state
maintain
cycl
mosquito
small
mammal
weaver
et
al
virus
serogroup
capabl
infect
larg
mammal
exampl
iab
ic
strain
associ
epizoot
spread
equin
infect
equin
act
amplif
host
replic
viru
may
transmit
human
mosquito
possibl
result
larg
outbreak
febril
ill
neurolog
diseas
weaver
et
al
virus
serogroup
appear
equinevirul
persist
stabl
enzoot
cycl
natur
transmiss
enzoot
virus
human
rare
may
associ
sever
diseas
johnson
martin
artifici
environ
laboratori
shown
strain
veev
readili
transmiss
via
airborn
rout
numer
laboratori
worker
accident
infect
way
lennett
koprowski
subcommitte
arboviru
laboratori
safeti
american
committe
arthropodborn
virus
attenu
live
vaccin
deriv
repeat
passag
virul
iab
strain
foetal
guinea
pig
heart
cell
berg
et
al
avail
immun
equin
current
licens
use
human
poorli
immunogen
human
pittman
et
al
caus
seriou
sideeffect
alevizato
et
al
casamassima
et
al
rayfield
et
al
addit
effect
antivir
drug
present
avail
use
veev
work
ongo
develop
new
veev
vaccin
suitabl
human
use
greenway
et
al
hodgson
et
al
kinney
et
al
phillpott
et
al
pratt
et
al
absenc
avail
effect
antivir
therapi
extrem
desir
short
interf
rna
sirna
small
doublestrand
rna
molecul
direct
degrad
complementari
messeng
rna
via
cellular
process
known
rna
interfer
sirna
incorpor
protein
complex
known
rnainduc
silenc
complex
risc
antisens
strand
sirna
guid
risc
target
rna
cleav
rna
interfer
evolutionari
conserv
mechan
within
eukaryot
function
includ
endogen
gene
regul
viral
defenc
mainten
genom
stabil
fountain
et
al
yet
proven
mammal
use
rna
interfer
viral
defenc
mechan
laboratori
introduct
sirna
mammalian
cell
use
inhibit
express
viral
gene
rna
interfer
shown
activ
mani
human
pathogen
virus
geisbert
et
al
reuter
et
al
tan
yin
includ
alphavirus
semliki
forest
viru
caplen
et
al
onyongnyong
viru
keen
et
al
effici
sequencespecif
natur
rna
interfer
rais
possibl
use
sirna
antivir
therapi
abil
pool
four
sirna
specif
inhibit
replic
six
human
pathogen
strain
veev
describ
bhk
vero
cell
line
european
collect
anim
cell
cultur
uk
propag
standard
method
use
recommend
cultur
media
transfect
procedur
see
section
cell
maintain
glasgow
minimum
essenti
medium
supplement
vv
foetal
calf
serum
mm
lglutamin
mm
hepe
vv
tryptos
phosphat
broth
gmm
viru
infect
see
section
viral
titrat
see
section
cell
maintain
leibovitz
media
supplement
vv
foetal
calf
serum
mm
lglutamin
mm
hepe
media
supplement
suppli
sigma
uk
strain
veev
serogroup
iab
trinidad
donkey
trd
ic
id
ie
mena
ii
ii
iii
kindli
suppli
dr
b
shope
yale
arboviru
research
unit
univers
texa
austin
tx
virul
viru
stock
prepar
titer
determin
describ
phillpott
et
al
work
virul
veev
carri
uk
advisori
committe
danger
pathogen
level
contain
strain
semliki
forest
viru
sfv
kindli
suppli
dr
p
bernard
viragen
scotland
ltd
edinburgh
uk
viru
grown
titer
determin
describ
genom
veev
strain
trd
mena
ii
genbank
access
no
respect
align
use
clone
manag
suit
softwar
sci
softwar
usa
area
conserv
sequenc
identifi
use
technolog
dharmacon
lafayett
co
design
synthesis
pool
four
doublestrand
sirna
conserv
sequenc
cat
individu
sirna
contain
within
veev
sirna
pool
shown
tabl
analysi
confirm
select
sirna
sequenc
present
genom
veev
strain
absent
sfv
human
mous
genom
veev
sirna
pool
four
individu
sirna
contain
within
pool
suppli
dharmacon
sirna
reconstitut
accord
manufactur
instruct
use
sirna
design
housekeep
gene
lamin
ac
qiagen
crawley
uk
pool
nontarget
sirna
dharmacon
cat
use
appropri
experi
ensur
specif
observ
effect
neg
control
sirna
lack
sequenc
homolog
veev
genom
rtpcr
perform
extract
veev
genom
rna
rneasi
mini
kit
qiagen
uk
use
primer
flank
four
sirna
target
site
readytogo
tm
rtpcr
bead
amersham
bioscienc
buckinghamshir
uk
amplifi
product
resolv
agaros
gel
electrophoresi
visualis
ethidium
bromid
stain
sequenc
amplifi
product
determin
sequenc
excis
band
high
pure
pcr
product
purif
kit
roch
buckinghamshir
uk
briefli
bhk
cell
transfect
sirna
design
veev
appropri
neg
control
sirna
cell
infect
veev
strain
h
transfect
amount
viru
cultur
supernat
ascertain
titrat
vero
cell
h
postinfect
except
one
experi
determin
veev
sirna
pool
maintain
viral
inhibit
longer
period
time
cultur
supernat
titrat
h
postinfect
initi
experi
determin
optim
condit
transfect
sirna
bhk
cell
briefli
cell
tabl
sequenc
locat
sirna
veev
sirna
pool
sirna
accord
appropri
genom
sequenc
genbank
databas
access
no
describ
section
l
gmm
plate
well
plate
corn
acton
cell
transfect
sirna
h
later
use
transfect
reagent
lipofectamin
tm
invitrogen
uk
accord
manufactur
guidelin
bhk
cell
infect
h
posttransfect
use
multipl
infect
moi
media
remov
l
viru
dilut
appli
monolay
incub
min
room
temperatur
l
care
ad
infect
cell
incub
h
one
experi
h
see
time
supernat
care
remov
store
c
titer
viru
supernat
determin
plaqu
format
wv
carboxymethyl
cellulos
overlay
vero
cell
briefli
cell
seed
plate
cell
well
incub
overnight
media
remov
cell
overlaid
l
viru
dilut
incub
min
roomtemperatur
ml
doublestrength
invitrogen
dilut
wv
carboxymethyl
cellulos
sigma
care
ad
well
cell
incub
h
fix
vv
formal
salin
h
stain
wv
crystal
violet
sigma
plaqu
count
amount
viru
calcul
student
ttest
oneway
anova
perform
use
minitab
tm
statist
softwar
minitab
tm
inc
wwwminitab
com
pool
sirna
design
target
area
conserv
sequenc
genom
six
strain
veev
sequenc
target
gene
four
individu
sirna
contain
within
pool
shown
tabl
found
imposs
design
sirna
conserv
six
veev
genom
strain
trd
serogroup
iab
serogroup
ic
serogroup
id
serogroup
ii
genet
similar
four
sirna
conserv
genom
strain
mena
ii
serogroup
ie
serogroup
iii
genet
divers
strain
trd
consequ
sirna
conserv
mena
ii
genom
none
sirna
conserv
genom
sequenc
sensestrand
sirna
target
site
mena
ii
genom
sirna
sirna
sequenc
sirna
target
site
genom
sirna
sirna
sirna
rna
virus
undergo
high
rate
mutat
due
errorpron
replic
rna
polymeras
therefor
possibl
genom
sequenc
veev
strain
use
work
differ
publish
genom
sequenc
reason
sirna
target
site
veev
genom
sequenc
found
target
site
sequenc
match
publish
genom
sequenc
result
shown
none
sirna
sequenc
conserv
genom
sirna
veev
sirna
pool
would
expect
activ
veev
strain
unless
mismatch
sirna
target
rna
could
toler
similarli
sirna
would
expect
activ
veev
strain
mena
ii
sequenc
conserv
mena
ii
genom
confirm
expect
activ
individu
sirna
make
veev
sirna
pool
tabl
test
veev
strain
trd
mena
ii
order
ensur
observ
antivir
activ
due
rna
interfer
rather
induct
interferon
ifn
bhk
cell
use
experi
cell
defect
ifn
product
fournier
et
al
liu
et
al
bhk
cell
transfect
nm
sirna
contain
veev
sirna
pool
nm
control
sirna
design
lamin
ac
bitko
barik
et
al
h
transfect
cell
infect
veev
strain
amount
viru
cultur
supernat
h
postinfect
ascertain
titrat
fig
viral
titer
affect
lamin
ac
sirna
virus
replic
extent
nontransfect
cell
result
shown
howev
individu
sirna
exert
signific
p
antivir
effect
veev
strain
trd
compar
viral
replic
control
cell
sirna
inhibit
replic
trd
respect
contrast
sirna
significantli
p
inhibit
replic
veev
strain
mena
ii
respect
compar
control
sirna
abl
significantli
p
inhibit
replic
veev
strain
compar
control
sequenc
sirna
conserv
mena
ii
genom
sirna
differ
genom
sequenc
singl
nucleotid
extrem
end
section
activ
sirna
strain
indic
mutat
posit
toler
howev
posit
number
mutat
remain
sirna
toler
result
lack
antivir
activ
strain
mena
ii
order
establish
differ
sirna
antivir
activ
bhk
cell
transfect
nm
sirna
transfect
cell
subsequ
infect
veev
strain
trd
amount
viru
cultur
supernat
h
postinfect
determin
titrat
fig
concentr
nm
individu
sirna
significantli
p
inhibit
replic
strain
trd
compar
viral
replic
cell
transfect
lamin
ac
sirna
howev
concentr
nm
sirna
exert
signific
p
antivir
activ
decreas
titer
compar
control
indic
sirna
effect
veev
experi
veev
strain
trd
determin
veev
sirna
pool
retain
antivir
activ
dilut
nm
activ
decreas
nm
fig
test
activ
veev
sirna
pool
multipl
strain
veev
bhk
cell
tran
fig
virus
replic
extent
cell
transfect
pool
nontarget
sirna
nontransfect
cell
result
shown
antivir
activ
veev
sirna
pool
statist
signific
p
six
veev
strain
sfv
demonstr
activ
sirna
pool
specif
veev
veev
sirna
pool
inhibit
replic
veev
compar
viral
replic
cell
transfect
pool
nontarget
sirna
although
result
obtain
individu
sirna
strain
fig
indic
sirna
possess
fig
specif
inhibit
viral
replic
pool
four
sirna
design
veev
titer
six
strain
veev
one
strain
sfv
grown
bhk
cell
transfect
nm
nontarget
sirna
pool
veev
sirna
pool
n
data
point
confid
interv
shown
p
antivir
activ
strain
veev
known
seemingli
inact
sirna
could
gain
activ
combin
veev
sirna
pool
test
bhk
cell
transfect
combin
sirna
sirna
alon
final
concentr
nm
infect
h
later
veev
strain
cultur
supernat
harvest
h
postinfect
titrat
comparison
strain
also
incub
presenc
nm
pool
nontarget
sirna
veev
sirna
pool
fig
sirna
alon
veev
sirna
pool
exert
signific
antivir
activ
p
decreas
titer
respect
compar
titer
cell
transfect
nontarget
sirna
pool
combin
sirna
inhibit
replic
strain
demonstr
sirna
sole
respons
antivir
activ
exhibit
veev
sirna
pool
strain
averag
inhibit
strain
greater
sirna
alon
veev
sirna
pool
like
reflect
greater
concentr
sirna
cell
transfect
sirna
alon
veev
sirna
pool
amount
viru
present
cultur
supernat
gener
determin
h
postinfect
howev
experi
cultur
supernat
harvest
h
postinfect
test
abil
veev
sirna
pool
inhibit
viral
replic
longer
time
period
nontransfect
cell
monolay
complet
lyse
h
incub
veev
although
signific
p
viral
inhibit
observ
h
postinfect
decreas
titer
inhibit
sustain
h
period
fig
rna
virus
high
mutat
rate
possibl
veev
mutat
overcom
effect
rna
interfer
test
three
sampl
viru
incub
presenc
sirna
pool
h
reexpos
veev
sirna
pool
fig
reexpos
viru
still
sensit
effect
veev
sirna
pool
h
period
decreas
titer
p
level
inhibit
indistinguish
observ
stock
fig
viru
previous
expos
veev
sirna
pool
h
remain
suscept
effect
rna
interfer
titer
strain
trd
grown
bhk
cell
transfect
nm
nontarget
sirna
pool
veev
sirna
pool
n
data
point
confid
interv
shown
p
veev
result
indic
veev
becom
resist
rna
interfer
instead
sirna
pool
caus
lag
viral
replic
appar
h
reduc
titer
h
viral
titer
caught
level
cell
transfect
nontarget
sirna
fig
resist
rna
interfer
continu
incub
sirna
observ
veev
strain
trd
strain
titer
strain
trd
b
c
cours
consecut
incub
sirna
viru
grown
bhk
cell
transfect
nm
lamin
ac
sirna
sirna
nm
nontarget
sirna
pool
veev
sirna
pool
viru
harvest
titrat
use
infect
cell
transfect
appropri
sirna
process
repeat
viru
undergon
exposur
sirna
n
data
point
confid
interv
shown
p
envisag
use
sirna
antivir
treatment
veev
infect
would
involv
multipledos
regim
result
viru
expos
sirna
extend
time
period
rna
virus
high
mutat
rate
strong
probabl
veev
escap
inhibitori
effect
rna
interfer
introduc
mutat
sirna
target
site
determin
abil
veev
overcom
rna
interfer
strain
trd
subject
consecut
incub
presenc
sirna
lamin
ac
sirna
pool
nontarget
sirna
veev
sirna
pool
fig
individu
sirna
use
test
whether
resist
mutat
aros
readili
presenc
singl
sirna
compar
pool
sirna
howev
case
veev
strain
trd
resist
sirna
pool
observ
four
exposur
whilst
resist
sirna
alon
observ
seven
exposur
fig
b
contrast
veev
strain
remain
suscept
either
individu
sirna
pool
sirna
throughout
experi
fig
rna
extract
viru
expos
consecut
incub
presenc
sirna
veev
sirna
pool
sequenc
sirna
target
site
analys
found
ident
conserv
sequenc
result
shown
first
studi
show
effect
rna
interfer
alphaviru
veev
first
demonstr
sirna
design
area
conserv
sequenc
specif
inhibit
replic
six
strain
viru
sirna
inhibit
strain
replic
sirna
respons
activ
veev
sirna
pool
viru
addit
sirna
could
design
strain
mena
ii
inclus
sirna
pool
individu
sirna
found
within
pool
inhibit
replic
veev
strain
trd
although
sirna
averag
least
effect
huesken
et
al
recent
describ
prefer
nucleotid
certain
posit
antisens
strand
activ
sirna
sirna
four
prefer
base
posit
posit
respect
sirna
three
prefer
nucleotid
posit
howev
one
base
prefer
present
posit
perhap
explain
lack
effect
compar
sirna
combin
four
sirna
caus
larg
increas
antivir
activ
strain
trd
accord
result
other
schubert
et
al
yuan
et
al
envisag
use
multipl
sirna
may
lead
satur
risc
therebi
reduc
incorpor
individu
sirna
complex
decreas
activ
howev
appear
taken
place
veev
sirna
pool
singl
base
pair
mismatch
end
sirna
affect
antivir
activ
veev
strain
mismatch
abolish
activ
strain
mena
ii
wide
observ
one
mismatch
sirna
target
toler
case
sever
mismatch
toler
review
see
dykxhoorn
lieberman
holen
du
et
al
recent
report
mutat
two
termin
nucleotid
either
end
target
site
well
toler
uracil
best
toler
mismatch
base
sirna
antisens
strand
posit
guanin
result
du
et
al
agreement
find
sirna
antivir
activ
strain
despit
base
pair
mismatch
posit
antisens
strand
sirna
g
u
pair
possibl
doubl
strand
rna
stimul
innat
antivir
defenc
mechan
lead
product
inflammatori
cytokin
type
interferon
nonspecif
inhibit
gene
express
receptor
involv
rna
recognit
includ
member
transmembran
tolllik
receptor
famili
tlr
cytosol
rnabind
protein
pkr
helicas
review
see
schlee
et
al
howev
evid
date
indic
short
synthet
sirna
duplex
detect
locat
endosom
membran
immun
cell
plasmacytoid
dendrit
cell
recognit
requir
presenc
specif
motif
hornung
et
al
judg
et
al
bhk
cell
use
experi
fibroblast
origin
defect
ifn
product
fournier
et
al
liu
et
al
none
sirna
contain
immunostimulatori
motif
describ
hornung
et
al
judg
et
al
seem
unlik
nonspecif
inhibit
gene
express
take
place
addit
replic
sfv
affect
cell
transfect
veev
sirna
pool
confirm
sirna
specif
inhibit
veev
replic
longterm
silenc
viral
protein
express
sirna
report
result
emerg
virus
resist
rna
interfer
da
et
al
gitlin
et
al
issu
need
address
sirna
use
therapeut
resist
caus
gener
mutat
sirna
target
site
problem
particularli
relev
rna
virus
exhibit
increas
genet
variat
due
errorpron
replic
ensur
sirna
remain
effect
viral
rna
sequenc
conserv
normal
invari
differ
strain
target
chang
et
al
dave
pomerantz
sever
viral
sequenc
simultan
target
chang
et
al
geisbert
et
al
gitlin
et
al
work
describ
util
approach
success
veev
strain
resist
rna
interfer
observ
strain
trd
mechan
sirna
resist
strain
trd
uncertain
mutat
occur
sirna
target
site
indic
escap
mutant
readili
aris
particular
conserv
area
sequenc
target
silent
mutat
alter
nucleotid
sequenc
affect
encod
amino
acid
potenti
prevent
recognit
target
rna
sirna
even
occur
number
mammalian
virus
shown
express
protein
function
suppressor
rna
interfer
review
see
kok
jin
zheng
et
al
viral
protein
bind
doubl
strand
rna
abl
protect
messeng
rna
degrad
sequest
sirna
prevent
format
activ
risc
capsid
protein
veev
contain
region
bind
specif
rna
strauss
strauss
mutat
may
occur
protein
led
increas
abil
sequest
sirna
therefor
increas
resist
rna
interfer
report
addit
mechan
suppress
rna
interfer
product
rna
subvert
host
cell
function
includ
inhibit
rna
interfer
pathway
review
see
sarnow
et
al
howev
type
rna
far
found
virus
dna
genom
make
unlik
explan
sirna
resist
veev
number
method
deliv
sirna
vivo
test
bitko
et
al
ge
et
al
geisbert
et
al
giladi
et
al
li
et
al
sioud
soutschek
et
al
zimmermann
et
al
liposom
formul
gener
use
bitko
et
al
ge
et
al
geisbert
et
al
sioud
zimmermann
et
al
simpl
intranas
administr
nake
sirna
shown
effect
respiratori
virus
bitko
et
al
induct
immun
respons
sirna
concern
futur
clinic
use
deliveri
method
may
role
play
geisbert
et
al
hornung
et
al
judg
et
al
sioud
target
sirna
specif
cell
would
therapeut
advantag
antibodi
song
et
al
zhang
et
al
peptid
ligand
schiffel
et
al
aptam
mcnamara
et
al
success
use
target
sirna
cancer
cell
vivo
date
rna
interfer
shown
effect
mous
model
hepat
b
viru
giladi
et
al
klein
et
al
mccaffrey
et
al
herp
simplex
viru
pallis
et
al
influenza
viru
ge
et
al
tompkin
et
al
parainfluenza
viru
bitko
et
al
respiratori
syncyti
viru
bitko
et
al
ebola
viru
guinea
pig
model
geisbert
et
al
sar
coronaviru
rhesu
macaqu
model
li
et
al
high
level
viral
inhibit
induc
veev
sirna
pool
suggest
sirna
may
activ
vivo
current
examin
although
level
inhibit
induc
sirna
pool
substanti
transient
natur
inhibit
suggest
singl
administr
sirna
could
use
cure
veev
infect
use
multipl
dose
sirna
avoid
risk
induc
viral
resist
howev
temporari
inhibit
viral
replic
may
allow
infect
host
enough
time
develop
immun
respons
capabl
overcom
veev
altern
sirna
could
use
therapeut
combin
antivir
compound
success
treat
infect
diseas
veev
may
necessari
deliv
sirna
brain
infect
individu
direct
inject
sirna
brain
effect
use
target
wide
rang
gene
fountain
et
al
ideal
sirna
would
administ
system
abl
cross
bloodbrain
barrier
shown
intraven
inject
pegyl
immunoliposom
connect
target
monoclon
antibodi
abl
deliv
sirna
across
bloodbrain
barrier
success
treat
intracrani
brain
cancer
zhang
et
al
altern
may
possibl
link
sirna
appropri
lipid
molecul
deliveri
across
bloodbrain
barrier
approach
shown
effect
deliv
cholesterolconjug
sirna
liver
jejunum
soutschek
et
al
pool
four
sirna
describ
offer
new
approach
futur
antivir
therapi
veev
howev
avoid
gener
resist
develop
effect
deliveri
method
crucial
sirna
use
therapeut
